Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Wallden, Brett
    • Other Affiliation: NanoString Technologies, Inc, Seattle, USA
  • Storhoff, James
    • Other Affiliation: NanoString Technologies, Inc, Seattle, USA
  • Nielsen, Torsten
    • Other Affiliation: Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute and British Columbia Cancer Agency, Vancouver, Canada
  • Dowidar, Naeem
    • Other Affiliation: NanoString Technologies, Inc, Seattle, USA
  • Schaper, Carl
    • Other Affiliation: Statistical consultant, New York, USA
  • Ferree, Sean
    • Other Affiliation: NanoString Technologies, Inc, Seattle, USA
  • Liu, Shuzhen
    • Other Affiliation: Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute and British Columbia Cancer Agency, Vancouver, Canada
  • Leung, Samuel
    • Other Affiliation: Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute and British Columbia Cancer Agency, Vancouver, Canada
  • Geiss, Gary
    • Other Affiliation: NanoString Technologies, Inc, Seattle, USA
  • Snider, Jacqueline
    • Other Affiliation: Washington University School of Medicine, St. Louis, USA
  • Vickery, Tammi
    • Other Affiliation: Washington University School of Medicine, St. Louis, USA
  • Davies, Sherri R
    • Other Affiliation: Washington University School of Medicine, St. Louis, USA
  • Mardis, Elaine R
    • Other Affiliation: Washington University School of Medicine, St. Louis, USA
  • Gnant, Michael
    • Other Affiliation: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Sestak, Ivana
    • Other Affiliation: Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
  • Ellis, Matthew J
    • Other Affiliation: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA
  • Perou, Charles
    • Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center, School of Medicine, Department of Genetics
  • Bernard, Philip S
    • Other Affiliation: Huntsman Comprehensive Cancer Center, Department of Pathology, Salt Lake City, USA
  • Parker, Joel
    • Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center, School of Medicine, Department of Genetics
Abstract
  • Abstract Background The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier and risk model on the NanoString nCounter Dx Analysis System intended for decentralized testing in clinical laboratories. Methods 514 formalin-fixed, paraffin-embedded (FFPE) breast cancer patient samples were used to train prototypical centroids for each of the intrinsic subtypes of breast cancer on the NanoString platform. Hierarchical cluster analysis of gene expression data was used to identify the prototypical centroids defined in previous PAM50 algorithm training exercises. 304 FFPE patient samples from a well annotated clinical cohort in the absence of adjuvant systemic therapy were then used to train a subtype-based risk model (i.e. Prosigna ROR score). 232 samples from a tamoxifen-treated patient cohort were used to verify the prognostic accuracy of the algorithm prior to initiating clinical validation studies. Results The gene expression profiles of each of the four Prosigna subtype centroids were consistent with those previously published using the PCR-based PAM50 method. Similar to previously published classifiers, tumor samples classified as Luminal A by Prosigna had the best prognosis compared to samples classified as one of the three higher-risk tumor subtypes. The Prosigna Risk of Recurrence (ROR) score model was verified to be significantly associated with prognosis as a continuous variable and to add significant information over both commonly available IHC markers and Adjuvant! Online. Conclusions The results from the training and verification data sets show that the FDA-cleared and CE marked Prosigna test provides an accurate estimate of the risk of distant recurrence in hormone receptor positive breast cancer and is also capable of identifying a tumor's intrinsic subtype that is consistent with the previously published PCR-based PAM50 assay. Subsequent analytical and clinical validation studies confirm the clinical accuracy and technical precision of the Prosigna PAM50 assay in a decentralized setting.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Wallden et al.
Language
  • English
Bibliographic citation
  • BMC Medical Genomics. 2015 Aug 22;8(1):54
Publisher
  • BioMed Central

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 12920_2015_article_129.pdf 2019-05-07 Public Download
file details 12920_2015_129_moesm11_esm.pdf 2019-05-07 Public Download
file details 12920_2015_129_moesm4_esm.doc 2019-05-07 Public Download
file details 12920_2015_129_moesm10_esm.doc 2019-05-07 Public Download
file details 12920_2015_129_moesm7_esm.pdf 2019-05-07 Public Download
file details 12920_2015_129_moesm1_esm.docx 2019-05-07 Public Download
file details 12920_2015_129_moesm9_esm.pdf 2019-05-07 Public Download
file details 12920_2015_129_moesm3_esm.pdf 2019-05-07 Public Download
file details 12920_2015_129_moesm2_esm.docx 2019-05-07 Public Download
file details 12920_2015_129_moesm5_esm.pdf 2019-05-07 Public Download